Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients (2017) Hartkopf AD, Graf J, Simoes E, Keilmann L, Sickenberger N, Gaß P, Wallwiener D, et al. Journal article Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy (2017) Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Liedtke C, et al. Journal article Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study (2017) Higgins M, Curigliano G, Dieras V, Kuemmel S, Kunz G, Fasching P, Campone M, et al. Journal article Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer (2017) Kolberg HC, Loevey G, Akpolat-Basci L, Stephanou M, Fasching P, Untch M, Hoffmann O, et al. Journal article No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival (2017) Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, et al. Journal article Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017) Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al. Journal article Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, et al. Conference contribution Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer (2017) Schramm A, Schochter F, Friedl TWP, De Greqorio N, Andergassen U, Alunni-Fabbroni M, Trapp E, et al. Journal article OLAPARIB IN GERMAN ROUTINE CLINICAL PRACTICE - INTERIM RESULTS OF THE NON-INTERVENTIONAL STUDY C-PATROL (2017) Marme F, Sehouli J, Welslau M, Schinkoethe T, El-Balat A, Fasching P, Glowik R, Hilpert F Conference contribution Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial (2017) Wallwiener M, Matthies L, Simoes E, Keilmann L, Hartkopf AD, Sokolov AN, Walter CB, et al. Journal article